Stock Scorecard
Stock Summary for Syndax Pharmaceuticals Inc (SNDX) - $20.49 as of 4/18/2024 10:39:26 PM EST
Total Score
9 out of 29
Currently on the following lists
None
Tim's Recommendation
Avoid
Growth List Algorithm Criteria for SNDX
Positive earnings growth | |
P/E ratio less than Industry P/E Ratio | |
P/E ratio less than Sector P/E Ratio | |
P/E ratio that is half the growth rate (or less) | |
Positive net cash position the past year and most recent quarter | |
Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
Positive net income past year and 12 trailing months | |
Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for SNDX
Revenue growing by at least 20% average per year over the last 5 years | |
Market Capitalization under 2 billion | |
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for SNDX
Declared an ex-dividend date | |
Forward annual dividend rate greater than 2 | |
Positive net cash position the past year and most recent quarter | |
Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
Current ratio most recent quarter greater than 2 |
Bonus Criteria for SNDX
P/E ratio less than five-year Average P/E ratio | |
Last Price to 52 Week Low Ratio Less Than 1 | |
Total Cash Per Share > Last Day Price | |
P/S Ratio < 1 | |
P/B Ratio < 1 |
Latest News for for SNDX
Financial Details for SNDX
Company Overview |
|
---|---|
Ticker | SNDX |
Company Name | Syndax Pharmaceuticals Inc |
Country | USA |
Description | Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. The company is headquartered in Waltham, Massachusetts. |
Sector Name | LIFE SCIENCES |
Industry Name | PHARMACEUTICAL PREPARATIONS |
Most Recent Quarter | 12/31/2023 |
Next Earnings Date | 5/6/2024 |
Stock Price History |
|
Last Day Price | 20.49 |
Last Day Price Updated | 4/18/2024 10:39:26 PM EST |
Last Day Volume | 1,223,522 |
Average Daily Volume | 1,157,925 |
52-Week High | 25.34 |
52-Week Low | 11.21 |
Last Price to 52 Week Low | 82.78% |
Valuation Measures |
|
Trailing PE | N/A |
Industry PE | 100.90 |
Sector PE | 61.34 |
5-Year Average PE | 4.28 |
Free Cash Flow Ratio | 3.05 |
Industry Free Cash Flow Ratio | 12.64 |
Sector Free Cash Flow Ratio | 30.17 |
Current Ratio Most Recent Quarter | 10.00 |
Total Cash Per Share | 6.72 |
Book Value Per Share Most Recent Quarter | 6.53 |
Price to Book Ratio | 3.33 |
Industry Price to Book Ratio | 5.66 |
Sector Price to Book Ratio | 22.08 |
Price to Sales Ratio Twelve Trailing Months | 12.67 |
Industry Price to Sales Ratio Twelve Trailing Months | 5.48 |
Sector Price to Sales Ratio Twelve Trailing Months | 5.19 |
Share Statistics |
|
Total Shares Outstanding | 84,980,000 |
Market Capitalization | 1,741,240,200 |
Institutional Ownership | N/A |
Dividends |
|
Ex-Dividend Date | N/A |
Last Dividend Amount | 0.00 |
Current Dividend Amount | 0.00 |
Dividend Aristocrat? | False |
Trailing Annual Dividend Rate | 0.00 |
Trailing Annual Dividend Yield | 0.00% |
Forward Annual Dividend Rate | 0.00 |
Forward Annual Dividend Yield | 0.00% |
5-Year Dividend Payments Count | 0 |
3-Year Average Dividend Yield | 0.00% |
5-Year Average Dividend Yield | 0.00% |
1-Year Dividend Growth Rate Percentage | 0.00% |
3-Year Dividend Growth Rate Percentage | 0.00% |
5-Year Dividend Growth Rate Percentage | 0.00% |
All-Time Dividend Growth Rate Percentage | 0.00% |
Dividend Payout Ratio | N/A |
Income Statement |
|
Quarterly Earnings Growth YOY | 0.00% |
Annual Earnings Growth | -40.19% |
Reported EPS 12 Trailing Months | -2.98 |
Reported EPS Past Year | 0.00 |
Reported EPS Prior Year | -2.96 |
Net Income Twelve Trailing Months | -209,360,000 |
Net Income Past Year | -209,360,000 |
Net Income Prior Year | -149,338,000 |
Quarterly Revenue Growth YOY | 33,297.00% |
5-Year Revenue Growth | 126.83% |
Balance Sheet |
|
Total Cash Most Recent Quarter | 570,698,000 |
Total Cash Past Year | 570,698,000 |
Total Cash Prior Year | 475,802,000 |
Net Cash Position Most Recent Quarter | 510,492,000 |
Net Cash Position Past Year | 510,803,336 |
Long Term Debt Past Year | 59,894,664 |
Long Term Debt Prior Year | 59,894,664 |
Total Debt Most Recent Quarter | 60,206,000 |
Equity to Debt Ratio Past Year | 0.90 |
Equity to Debt Ratio Most Recent Quarter | 0.90 |
Total Stockholder Equity Past Year | 554,196,000 |
Total Stockholder Equity Prior Year | 467,449,000 |
Total Stockholder Equity Most Recent Quarter | 554,196,000 |
Options |
|
Put/Call Ratio | 4.67 |
Has Options | Options Chain |
Liquidity Rating | |
Technical Analysis |
|
Yahoo Finance Chart | Yahoo Finance Chart |
MACD | -0.08 |
MACD Signal | 0.04 |
20-Day Bollinger Lower Band | 17.56 |
20-Day Bollinger Middle Band | 21.64 |
20-Day Bollinger Upper Band | 25.73 |
Beta | 0.98 |
RSI | 45.36 |
50-Day SMA | 19.44 |
200-Day SMA | 19.56 |
System |
|
Modified | 4/18/2024 11:52:12 AM EST |